165 related articles for article (PubMed ID: 8453619)
1. Chronopharmacology of high-dose busulfan in children.
Vassal G; Challine D; Koscielny S; Hartmann O; Deroussent A; Boland I; Valteau-Couanet D; Lemerle J; Lévi F; Gouyette A
Cancer Res; 1993 Apr; 53(7):1534-7. PubMed ID: 8453619
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.
Vassal G; Deroussent A; Hartmann O; Challine D; Benhamou E; Valteau-Couanet D; Brugières L; Kalifa C; Gouyette A; Lemerle J
Cancer Res; 1990 Oct; 50(19):6203-7. PubMed ID: 2400986
[TBL] [Abstract][Full Text] [Related]
4. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors.
Bouligand J; Le Maitre A; Valteau-Couanet D; Grill J; Drouard-Troalen L; Paci A; Hartmann O; Benhamou E; Vassal G
Clin Pharmacol Ther; 2007 Oct; 82(4):402-9. PubMed ID: 17392724
[TBL] [Abstract][Full Text] [Related]
5. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
6. Association of busulfan area under the curve with veno-occlusive disease following BMT.
Dix SP; Wingard JR; Mullins RE; Jerkunica I; Davidson TG; Gilmore CE; York RC; Lin LS; Devine SM; Geller RB; Heffner LT; Hillyer CD; Holland HK; Winton EF; Saral R
Bone Marrow Transplant; 1996 Feb; 17(2):225-30. PubMed ID: 8640171
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
Vassal G
Anticancer Res; 1994; 14(6A):2363-70. PubMed ID: 7825973
[TBL] [Abstract][Full Text] [Related]
8. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
9. High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
Diaz MA; Vicent MG; Madero L
Bone Marrow Transplant; 1999 Dec; 24(11):1157-9. PubMed ID: 10642802
[TBL] [Abstract][Full Text] [Related]
10. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
11. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.
Méresse V; Hartmann O; Vassal G; Benhamou E; Valteau-Couanet D; Brugieres L; Lemerle J
Bone Marrow Transplant; 1992 Aug; 10(2):135-41. PubMed ID: 1525602
[TBL] [Abstract][Full Text] [Related]
13. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.
Vassal G; Koscielny S; Challine D; Valteau-Couanet D; Boland I; Deroussent A; Lemerle J; Gouyette A; Hartmann O
Cancer Chemother Pharmacol; 1996; 37(3):247-53. PubMed ID: 8529285
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
15. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
Grochow LB
Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
[TBL] [Abstract][Full Text] [Related]
16. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
[TBL] [Abstract][Full Text] [Related]
18. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation.
Copelan EA; Bechtel TP; Avalos BR; Elder PJ; Ezzone SA; Scholl MD; Penza SL
Bone Marrow Transplant; 2001 Jun; 27(11):1121-4. PubMed ID: 11551021
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule.
Madden T; de Lima M; Thapar N; Nguyen J; Roberson S; Couriel D; Pierre B; Shpall EJ; Jones RB; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2007 Jan; 13(1):56-64. PubMed ID: 17222753
[TBL] [Abstract][Full Text] [Related]
20. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?
Schuler U; Schroer S; Kühnle A; Blanz J; Mewes K; Kumbier I; Proksch B; Zeller KP; Ehninger G
Bone Marrow Transplant; 1994 Nov; 14(5):759-65. PubMed ID: 7889009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]